INHX Inhibitex, Inc. (MM)

Inhibitex, Inc. (NASDAQ:INHX) announced today that it will host a conference call on Tuesday, August 12, 2008 at 8:30 a.m. EDT to review the Company�s second quarter financial results and provide an update on recent corporate developments. The Company will issue a press release regarding its second quarter financial results on the same day, prior to the conference call. To access the conference call, please dial 888-680-0878 (domestic) or 617-213-4855 (international) and reference the access code 29157221. A replay of the call will be available from 10:30 a.m. EDT on August 12 , until September 12 , 2008 at midnight. To access the replay, please dial 888-286-8010 (domestic) or 617-801-6888 (international) and reference the access code 72288440. A live audio webcast of the call and the archived webcast will be available in the News and Events section of the Inhibitex website at http://www.inhibitex.com. About Inhibitex Inhibitex, Inc., headquartered in Alpharetta, Georgia, is a biopharmaceutical company focused on developing products to treat and prevent serious infectious diseases. The Company�s pipeline includes FV-100, its clinical-stage oral nucleoside analogue in development for the treatment of herpes zoster (shingles), as well as a series of pre-clinical stage HCV polymerase inhibitors and HIV integrase inhibitors. Inhibitex has also licensed certain of its proprietary MSCRAMM� protein technology to Wyeth for the development of staphylococcal vaccines and to 3M for the development of diagnostics. For additional information about the Company, please visit www.inhibitex.com.